MedTrace Logo

The Research of Standard Diagnosis and Treatment for HSPN in Children

NCT02532777 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-02-26

No results posted yet for this study

Summary

This study is performed to evaluate the efficacy and safety of various measures in the treatment of HSPN in children.

Conditions

  • Henoch-Schoenlein Purpura Nephritis

Interventions

DRUG

Prednisone

DRUG

Cyclophosphamide(CTX)

DRUG

Mycophenolate mofetil(MMF)

DRUG

Leflunomide(LEF)

DRUG

Angiotensin-converting enzyme inhibitor(ACEI)

DRUG

Methylprednisolone

Sponsors & Collaborators

  • Nanjing Children's Hospital

    lead OTHER

Principal Investigators

  • Aihua Zhang, M.D. · Department of Nephrology, Nanjing children's hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02532777 on ClinicalTrials.gov